EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical characteristics and risk factors analysis of Clostridioides difficile infection in ulcerative colitis patients during biologic therapy

Tingting Xu, Ying Xie

Frontiers in Cellular and Infection Microbiology · 27.03.2026 · 16

DOI: 10.3389/fcimb.2026.1803104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 27.03.2026. Verfasst von Tingting Xu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Clostridium Infections, Clostridioides difficile, Biological Therapy. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the risk factors for Clostridioides difficile infection (CDI) in patients with ulcerative colitis (UC) during biologic therapy.

Methods

Patients diagnosed with UC who received Infliximab (IFX) or Vedolizumab (VDZ) were enrolled. Their clinical characteristics and risk factors for CDI were analyzed.

Results

A total of 110 UC patients treated with IFX (61 cases) or VDZ (49 cases) were included. The overall positive rate of Clostridioides difficile ( C. difficile ) was 28.2%. Positive Epstein-Barr virus (EBV)-DNA, a modified Mayo score ≥11 points, and a history of glucocorticoids use within 2 months before admission were independent risk factors for CDI in UC patients receiving IFX/VDZ therapy. The incidence of CDI was the highest within 0–3 months after IFX/VDZ treatment.

Conclusion

Positive EBV-DNA, a modified Mayo score ≥11 points, and a history of glucocorticoids use within 2 months before admission were independent risk factors for CDI in UC patients during IFX/VDZ therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeClostridium InfectionsClostridioides difficileBiological TherapyHumansRisk FactorsFemaleInfliximabAdultAntibodies, Monoclonal, HumanizedMaleMiddle AgedIncidenceHerpesvirus 4, Human

Stichwörter der Autor:innen

Clostridioides difficile infectionInfliximabVedolizumabrisk factorsulcerative colitis

Substanzen

InfliximabAntibodies, Monoclonal, Humanizedvedolizumab

Autor:innen und Institutionen

  • Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

Zitieren

APA

Xu, T., & Xie, Y. (2026). Clinical characteristics and risk factors analysis of Clostridioides difficile infection in ulcerative colitis patients during biologic therapy. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1803104

Vancouver

Xu T, Xie Y. Clinical characteristics and risk factors analysis of Clostridioides difficile infection in ulcerative colitis patients during biologic therapy. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1803104

BibTeX
@article{Xu2026,
  author = {Xu, Tingting and Xie, Ying},
  title = {Clinical characteristics and risk factors analysis of Clostridioides difficile infection in ulcerative colitis patients during biologic therapy},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1803104}
}
Kostenlos starten →